These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32771209)

  • 1. First-ever treatment in multiple sclerosis.
    Pantazou V; Pot C; Du Pasquier R; Le Goff G; Théaudin M
    Rev Neurol (Paris); 2021; 177(1-2):93-99. PubMed ID: 32771209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
    Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
    J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study.
    Diem L; Daponte A; Findling O; Miclea A; Briner M; Salmen A; Gold R; Kilidireas C; Chan A; Evangelopoulos ME; Hoepner R
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31937596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
    Vollmer BL; Nair KV; Sillau S; Corboy JR; Vollmer T; Alvarez E
    Ann Clin Transl Neurol; 2019 Feb; 6(2):252-262. PubMed ID: 30847358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.
    Vollmer B; Ontaneda D; Bandyopadhyay A; Cohn S; Nair K; Sillau S; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
    Neurol Clin Pract; 2018 Aug; 8(4):292-301. PubMed ID: 30140580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.
    Vollmer B; Nair KV; Sillau SH; Corboy J; Vollmer T; Alvarez E
    Mult Scler J Exp Transl Clin; 2017; 3(3):2055217317725102. PubMed ID: 28839949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    Lattanzi S; Danni M; Taffi R; Cerqua R; Carlini G; Pulcini A; Provinciali L; Silvestrini M
    J Neurol; 2017 Nov; 264(11):2325-2329. PubMed ID: 28831550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.
    Hersh CM; Altincatal A; Belviso N; Kapadia S; de Moor C; Rudick R; Williams JR; Miller C; Koulinska I
    Mult Scler J Exp Transl Clin; 2022; 8(1):20552173211069852. PubMed ID: 35024161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod.
    Salter A; Lancia S; Cutter G; Marrie RA; Mendoza JP; Lewin JB; Fox Mellen RJ
    Ther Adv Neurol Disord; 2021; 14():17562864211021177. PubMed ID: 34262613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a "common" first line treatment.
    Pantazou V; Du Pasquier R; Pot C; Le Goff G; Théaudin M
    Rev Neurol (Paris); 2021 Oct; 177(8):935-940. PubMed ID: 33637293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis.
    Reynolds A; Gaughan M; Holden D; Redenbaugh V; Dunne J; Redmond J; Conlon N
    Ir J Med Sci; 2022 Dec; 191(6):2759-2762. PubMed ID: 35028898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
    Bosco-Lévy P; Debouverie M; Brochet B; Guillemin F; Louapre C; Maillart E; Heinzlef O; Lignot S; Diez P; Abouelfath A; Lassalle R; Blin P; Droz-Perroteau C
    Br J Clin Pharmacol; 2022 Mar; 88(3):1268-1278. PubMed ID: 34505304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.
    Pilo de la Fuente B; Sabín J; Galán V; Thuissard I; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Lozano-Ros A; García-Domínguez JM; Borrego L; Ayuso L; Castro A; Sánchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodríguez-García E; Andreu-Vázquez C; Blasco R; García-Merino JA; Aladro Y;
    CNS Drugs; 2020 Dec; 34(12):1275-1286. PubMed ID: 33226562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Prosperini L; Lucchini M; Haggiag S; Bellantonio P; Bianco A; Buscarinu MC; Buttari F; Centonze D; Cortese A; De Giglio L; Fantozzi R; Ferraro E; Fornasiero A; Francia A; Galgani S; Gasperini C; Marfia GA; Millefiorini E; Nociti V; Pontecorvo S; Pozzilli C; Ruggieri S; Salvetti M; Sgarlata E; Mirabella M
    Neurology; 2018 Jul; 91(2):e153-e161. PubMed ID: 29875218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.